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Bauer alkylamide 11 and Bauer ketone 23 were previously found to be partially responsible for
Echinacea angustifolia anti-inflammatory properties. This study further tested their importance using
the inhibition of prostaglandin E2 (PGE2) and nitric oxide (NO) production by RAW264.7 mouse
macrophages in the absence and presence of lipopolysaccharide (LPS) and E. angustifolia extracts,
phytochemical enriched fractions, or pure synthesized standards. Molecular targets were probed
using microarray, qRT-PCR, Western blot, and enzyme assays. Fractions with these phytochemi-
cals were more potent inhibitors of LPS-induced PGE2 production than E. angustifolia extracts.
Microarray did not detect changes in transcripts with phytochemical treatments; however, qRT-PCR
showed a decrease in TNF-R and an increase of iNOS transcripts. LPS-induced COX-2 protein was
increased by an E. angustifolia fraction containing Bauer ketone 23 and by pure phytochemical.
COX-2 activity was decreased with all treatments. The phytochemical inhibition of PGE2 production
by Echinacea may be due to the direct targeting of COX-2 enzyme.
KEYWORDS: Echinacea angustifolia; prostaglandin E2; nitric oxide; Bauer alkylamides; Bauer ketones;
anti-inflammatory; fractionation
INTRODUCTION
Echinacea has been used medicinally for hundreds of years for
the treatment of numerous ailments, including inflammation (1),
and for the stimulation of the immune system (2). Several studies
have been conducted to elucidate the cellular mechanism of action
for the immune modulatory properties of Echinacea (3-6). These
studies have mainly focused on one particular class of compounds
of Echinacea, alkylamides, and their ability to interact with can-
nabinoid receptors.
The cannabinoid receptors, CB1 and CB2, are G protein
coupled receptors that have been implicated in the modulation of
the central nervous system and the inflammatory response. CB1
receptors occur in neurons from the central and peripheral nervous
system and are concentrated in the brain, whereas CB2 receptors
occur mainly in immune cells, including macrophages (7). Studies
attempting to unravel the mechanism of action for the immune
modulatory effects of Echinacea have led to the finding that
alkylamides, which are a class of constituents prominent in certain
Echinacea species, can act as cannabinomimetics (8). Endogenous
ligands for the cannabinoid receptors including anandamide (AEA)
and 2-arachidonyl glycerol (2-AG) share structural similarity with
Echinacea alkylamides (9). Previous studies have determined that
certain alkylamideshave the ability tobind to theCB2 receptorwith
Ki values around 60 nM with greater affinity than the natural
ligands (8). The evidence for CB2 receptor involvement in the
immune modulatory effect of Echinacea was further strengthened
byGertsch et al., who provided evidence that the gene expression of
an important inflammatory cytokine released bymacrophage cells,
tumor necrosis factor alpha (TNF-R), was induced via the CB2
receptor by a commercial preparation of Echinacea called Echina-
force (4). This activity was attributed to certain alkylamides present
in the Echinaforce preparation, including Bauer alkylamide 11 at
0.5 μM (the Bauer numbers are from ref 10). Recently, Echinacea
ketones have also been shown to have antitumorigenic and anti-
inflammatory properties in human cancer cells and mouse macro-
phage cells, respectively (11, 12). Therefore, Egger et al. set out to
determine whether various ketoalkenes of Echinacea pallida
couldmediate immunemodulatory effects through the cannabinoid
receptors; using a steady-state GTPase assay to assess cannabinoid
receptor antagonistic activity, they identified no significant activity
with the ketoalkenes from E. pallida (3).
Significant inhibition of prostaglandin E2 (PGE2) and nitric
oxide (NO) production have been achievable with treatments
of Echinacea extracts, purified fractions, and pure constituents
providing two excellent end points for the elucidation of species,
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aswell as classes of compounds, that are important for the in vitro
anti-inflammatory properties of Echinacea (12-15). Upstream
enzymes of these end points, such as cyclooxygenase-2 (COX-2)
and inducible nitric oxide synthase (iNOS), for PGE2 and NO,
respectively, havebeen studied to further delineate howEchinacea
modulates inflammation. Muller-Jakic et al. determined that
alkylamides isolated from a Soxhlet n-hexane extract of Echina-
cea angustifolia were capable of inhibiting both cyclooxygenase
and 5-lipoxygenase activity in vitro (16). Another study showed
that certain alkylamides from a CO2 extract of E. angustifolia
abrogated COX-2 activity, but had no effect on COX-2 mRNA
or protein in neuroglioma cells (17). Zhai et al. described the
inhibition of NO identified with Soxhlet ethanol extracts of
E. angustifolia, E. pallida, and Echinacea purpurea as being due
to an inhibition of iNOSprotein expression, attributing this effect
to the lipophilic alkylamides (15).
The presence of Bauer alkylamide 11 at a concentration of
3.55 μM and Bauer ketone 23 at a concentration of 0.83 μM in
E. angustifolia fractions capable of inhibiting PGE2 production
was a key finding in our laboratory (12). During a refractionation
of E. angustifolia we identified a fraction capable of significant
PGE2 inhibition, but the potency of this inhibitory activity was
less than previously identified in our prior studies.We determined
that the decreased inhibitory activity may be due to the lower
concentration of Bauer alkylamide 11 and the absence of Bauer
ketone 23 in the new fraction. This observation led to the hypo-
thesis that these two constituents at the proper concentration
ratios in E. angustifolia fractions may target specific bioactivities.
Our studies were conducted to understand the anti-inflammatory
roles, via inhibition of PGE2 and NO production, of Bauer
alkylamide 11 and Bauer ketone 23 in an E. angustifolia fraction
and elucidate amechanism of action leading to themodulation of
these inflammatory end points in the RAW264.7 mouse macro-
phage cell line.
MATERIALS AND METHODS
Plant Material and Extraction. E. angustifolia (PI636395) root
material from a 2008 harvest was grown in Ames, IA, by the USDA
North Central Regional Plant Introduction Station (NCRPIS, Ames, IA)
and collected, stored, and Soxhlet extracted with 95% ethanol as pre-
viously described (13). Further information about the accessions and
requests for the germplasm can be found on the Germplasm Resources
Information Network database at http://www.ars-grin.gov/npgs/acc/
acc_queries.html provided by NCRPIS.
Semipreparative HPLC Fractionation. The fractionation of a 95%
ethanol extract of E. angustifolia was performed using semipreparative
reversed-phase HPLCwith methods to avoid endotoxin contamination as
previously described (12). Five fractions were produced from the fraction-
ation, with the alkylamide-rich fraction 3 responsible for the majority of
identified bioactivity described under Results. The activity associated with
fraction 3 fromE. angustifolia in the present study was consistent with our
previous work (10, 11).
GC-MS Analysis. GC-MS analyses was used to determine concen-
trations of known compounds present in E. angustifolia fractions through
the use of synthetic standards as described by LaLone et al. (12).
Alkylamide and Ketone Synthesis.Alkylamide and ketone synthesis
was conducted as described previously, accounting for percent purity
when determining concentrations of compounds (12, 13).
Cell Culture. RAW264.7 mouse monocyte/macrophage cells were
purchased from American Type Culture Collection (catalog: TIB-71;
Manassas, VA). The conditions under which the cells were cultured have
been previously described (13, 18).
E. angustifolia Fraction and Constituent Treatments. Five treat-
ments were consistently used for each assay: (1)E. angustifolia fraction 3 at
1 μg/mL; (2) enriched fraction 3 consisting of E. angustifolia fraction 3 at
1 μg/mL (which contained Bauer alkylamide 11 at a concentration of
0.05μM), syntheticBauer alkylamide 11 at 3.5 μM,andBauer ketone 23 at
0.83 μM; (3) the combination of Bauer alkylamide 11 at 3.55 μM and
Bauer ketone 23 at 0.83 μM; (4) chemically synthesized Bauer alkylamide
11 at 3.55 μM; and (5) chemically synthesized Bauer ketone 23 at 0.83 μM.
Measurement of PGE2, NO, and Cytotoxicity. The production of
PGE2 was assessed using a PGE2 enzyme immunoassay (GE Biosciences,
Piscataway, NJ) after treatment of RAW264.7 mouse macrophage cells
for 8 h with fractions from E. angustifolia and with or without lipopoly-
saccharide (Escherichia coli O26:B6, Sigma, St. Louis, MO) as previously
described (13). Quercetin (3,5,7,30,40-pentahydroxyflavon) was chosen as
the positive control for this assay due to its anti-inflammatory properties at
a concentration of 10 μM (Sigma).
NO production was analyzed after a 24 h incubation with Echinacea
fraction or pure constituent using Griess Reagent System (Promega,
Madison, WI) following the manufacturer’s protocol. The assay has been
previously described using the RAW264.7 cell line and outlined in LaLone
et al. (12).
Cytotoxicity was analyzed using the Celltiter96 Aqueous One Solution
Cell Proliferation Assay (Promega) as previously described (13). All frac-
tions and compounds were screened for cytotoxicity at the concentrations
in the PGE2 assay and incubated for 24 h.
Western Blots. RAW264.7 cells were grown in 10 cm Petri dishes to
80% confluency (overnight) and treated for 8 h. Cells were washed twice
with ice-cold 1 phosphate-buffered saline (PBS) and lysed on ice for
5 min with 500 μL of lysis buffer (50 mM Tris-HCl, 2 mM ethylenedi-
aminetetraacetic acid, 2 mM ethylene glycol tetraacetic acid, 150 mM
sodium chloride, 2 mM phenylmethanesulfonyl fluoride, 25 mM leupeptin,
10mMaprotinin, 10mM sodium fluoride, 10mMsodiumorthovanadate,
10 mM sodium pyrophosphate, 0.5% Triton X-100). After lysis, the cells
were collected using a rubber policeman and centrifuged at 4 C to form a
cell pellet. The supernatant was isolated, and the protein concentration in
the cell lysate was identified using the BCAProteinAssayReagent (Pierce,
Rockford, IL). COX-1 (sc-19998), COX-2 (sc-19999), iNOS (sc-7271), and
R-tubulin (sc-8035) mouse monoclonal antibodies (Santa Cruz Bio-
technology, Santa Cruz, CA) were diluted 1:2000, 1:1000, 1:600, and 1:2000,
respectively, in 5% milk Tris-buffered saline containing 0.5% Tween-20.
Immunoblot separation was carried out as described by Przybyszewski
et al. (19) and visualized using ECL detection. Quantity One software was
used for semiquantitative analysis as previously described (18).
RNA Extraction and DNase Digestion. RAW264.7 mouse macro-
phage cells were grown in 75 cm flasks to 80% confluency and treated for
8 h for the microarray study. The cells were grown in 6-well plates to 80%
confluency for the qRT-PCR studies collected at six separate time points
(0.5, 1, 2, 4, 8, and 24 h). The treatments selected for the qRT-PCR studies
were E. angustifolia fraction 3, enriched fraction 3, the combination of
Bauer alkylamide 11 and Bauer ketone 23, and these constituents indivi-
dually. These treatments were incubated with and without LPS. Cells were
collected using a rubber policeman after the flask or plate had beenwashed
twice with PBS. The Trizol method (Invitrogen, Carlsbad, CA) of extrac-
tionwas used to isolateRNA, and further purificationwas carried out using
an RNeasy purification kit in combination with an RNase-free DNase kit
(Qiagen, Valencia, CA). Following extraction, RNA was analyzed for
quality and quantity using an Agilent Bioanalyzer 2100 and RNA Nano
6000 Labchip kit (Agilent Technologies, Palo Alto, CA).
Microarray. The microarray experiment was carried out using the
GeneChip Mouse Genome 430A 2.0 Array, which consisted of approxi-
mately 22600 probe sets, representing 14500 well-substantiated genes
(Affymetrix, Santa Clara, CA). The five treatments selected for the micro-
array analysis were themediumþDMSOandmediumþDMSOþ LPS con-
trols and E. angustifolia fraction 3 (1 μg/mL) þ LPS, fraction 3 (1 μg/mL) þ
synthetic Bauer alkylamide 11 (3.5 μM) þ Bauer ketone 23 (0.83 μM) þ
LPS, and synthetic Bauer alkylamide 11 (3.55 μM) þ Bauer ketone 23
(0.83 μM) þ LPS. The controls were used to establish that the LPS effect
was consistent with current literature on microarray studies with RAW264.7
macrophages.Our studywas todetermine differentially expressed (DE) genes
important for the inhibition of LPS-induced PGE2 production; therefore,
treatments without LPS were not included in the microarray study. Four
replicates of each treatment were analyzed on separate chips, and RNA
labeling was performed according to the manufacturer’s recommendations
(Affymetrix). The gene chips were run using a Gene Chip fluidics station
450 and a GeneChip Scanner 3000 7G conducted at the Gene Chip Facility
at Iowa State University.
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qRT-PCR. An iScript cDNA synthesis kit (Bio-Rad, Hercules, CA)
was used to reverse-transcribeRNA to cDNA. Primers were designedwith
anannealing temperature of 55 C forCOX-1,COX-2, TNF-R, iNOS, and
GADPH using Primer3 (20) and ordered from Integrated DNA Techno-
logies, Inc. (Coralville, IA) (Table 1). Amplification conditions for the
qRT-PCRwere set at 95 C for 3 min and 40 cycles of 95 C for 30 s, 56 C
for 30 s, and 72 C for 30 s, followedby95 C for 1min and 55 C for 1min.
Plasmid preparation for standard curves has been described pre-
viously (21), with the exception that PCR products were cloned into
MAX Efficiency DH5R Competent Cells.
COX Activity Assay. COX activity was measured using a COX
Fluorescent Activity AssayKit according to the manufacturer’s directions
(Cayman Chemicals, Ann Arbor, MI) after an 8 h treatment with
E. angustifolia fraction 3, enriched fraction 3, and the combination of
Bauer alkylamide 11 and Bauer ketone 23, as well as these constituents
individually (with and without LPS). The assay measures the peroxidase
component of the cyclooxygenase enzymes by monitoring the reaction
betweenPGG2and 10-acetyl-3,7-dihydroxyphenoxazine after the addition
of arachidonic acid, which generates the fluorescent compound resorufin.
The common plant flavonoid, quercetin, was used as a positive control
at 25 μM.
Milliplex. RAW264.7 cells were plated in 24-well plates (1.57
105 cells/well) and grown overnight. The treatments that were selected
for analysis were the E. angustifolia fraction 3, enriched fraction 3, the
combination of Bauer alkylamide 11 and Bauer ketone 23, and these
constituents individually. Each treatment was applied with and without
LPS induction (1 μg/mL) and treated for 24 h.After the 24 h treatment, the
supernatant was collected for the assay. A 32-plex Millipore cytokine/
chemokine kit was used to analyze cell supernatants on a multiplex assay
system (Bioplex, Bio-Rad).
Statistical Analysis. Both log transformed PGE2 data and NO data
and COX activity data were analyzed using randomized complete block
designwith several levels of treatment, followed by a t test based on a pooled
error variance to determine statistical significance compared to the (mediumþ
DMSO þ LPS) control. In all figures, the data are represented as percent
of control ( standard error, normalizing the (medium þ DMSO þ LPS)
control to 100% PGE2 or NO production within each block and sum-
marizing across all blocks to obtain the mean and standard error. The
three subsamples of cytotoxicity values in each blockwere averaged before
analysis as a randomized complete block design as above. The cytotoxicity
data are also presented as percent of control( standard error, normalizing
the (mediumþDMSO) control to 100% cell survival. The qRT-PCRdata
Table 1. Primers Used for qRT-PCR Analysis
gene primer oligonucleotide sequence (50-30)
COX-1 S CCTCACCAGTCAATCCCTGT
AS GTAGCCCGTGCGAGTACAAT
COX-2 S TTGGGGAGACCATGGTAGAG
AS GCTCGGCTTCCAGTATTGAG
TNF-R S AGGAGGGAGAACAGAAACTC
AS AATGAGAAGAGGCTGAGACA
iNOS S GTCTTGGTGAAAGTGGTGTT
AS GTGCTTGCCTTATACTGGTC
GAPDH S CAATGTGTCCGTCGTGGAT
AS AGCCCAAGATGCCCTTCAG
Figure 1. (A) Fraction 3 from a 2009 extract of Echinacea angustifolia (PI631293) significantly inhibited PGE2 production in RAW264.7 cells. The black bars
represent PGE2 levels after induction with 1 μg/mL LPS and treatment with an Echinacea fraction or ethanol extract (N = 3). All treatments þ LPS were
compared to mediumþ DMSOþ LPS control that was set at 100% (4.3 ng/mL). Treatments were also performed without LPS induction showing significant
reduction in PGE2 production with fractions 2, 3, and 5 (p < 0.04). The treatments without LPS were compared to the mediumþ DMSO control set at 100%
(0.03 ng/mL). / and // are representative of p < 0.05 and p < 0.01, respectively. Each bar represents percent of control( standard error. Parallel cytotoxicity
screens were conducted yielding no significant cytotoxicity with any of the fractions or the extract (data not shown). (B) Gas chromatography analysis of
bioactive fraction 3 from E. angustifolia. Total ion chromatograms of fraction 3 with peaks for which chemical identity was established by comparing their
retention times andmass spectra to authentic standards: Bauer alkylamide 13 (1), Bauer alkylamide 12 (2), Bauer alkylamide 10 (3), Bauer alkylamide 11 (4),
Bauer alkylamide 8/9 (5), and Bauer alkylamide 14 (6). Quantification of Bauer alkylamide 11 yielded a concentration of 0.05 μM.
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were analyzed using two-way ANOVA for the log starting quantity with
treatment and time as factors. Each treatment was compared to the
medium þ DMSO þ LPS control. Western blot analysis was previously
described (22). All statistical analysis was conducted using the GLM
procedures in SAS (version 9.1, SAS Institute Inc., Cary, NC).
The microarray experiment had a randomized complete block design
with four replications as fixed block and five treatments (medium þ
DMSO,mediumþDMSOþLPS, fraction 3þLPS, enriched fraction 3þ
LPS, Bauer alkylamide 11þBauer ketone 23þLPS). Within each
replication, the cultured cells and gene chips were randomly assigned to
receive one of the five treatments. The raw data were normalized by the
robust multiarray average method (RMA) using the affy package in
Bioconductor 2.0.8. The log expression data were then analyzed with SAS
version 9.1.
All of the pairwise comparisons of interest were tested by unadjusted
t test. Differentially expressed genes were identified with a false discovery
rate (FDR) of <0.001% using Benjamini and Hochberg’s method (23).
Genes with significant treatment effects (FDR<0.001%) were included
in a hierarchical cluster analysis. The standardized averages for each
treatment of each gene were used to compute a Euclidean distance matrix.
The average linkage method was used to measure the distance between
clusters. The analysis was done in R version 2.5.1.
RESULTS
Enrichment ofE. angustifoliaFraction.Semipreparative reversed
phase HPLC was used to fractionate an extract of root material
from E. angustifolia into five fractions, and these fractions were
analyzed for their effect on LPS-induced PGE2 production in the
RAW264.7mousemacrophage cell line. The study led to the identi-
fication of three fractions that were capable of significantly inhibit-
ing PGE2 production (Figure 1A). Fraction 3, an alkylamide-rich
fraction equivalent in preparation to the E. angustifolia fraction 3
(inhibited to 1.1 ng/mL PGE2) published by LaLone et al. (10),
showed potent PGE2 reduction compared to mediumþDMSO
control (1.8 ng/mL PGE2) at a concentration as low as 1 μg/mL
(Figure 1B). GC-MS analysis was conducted to identify the
prominent constituents present in fraction 3, as well as to quantify
the concentrations of Bauer alkylamide 11 and Bauer ketone 23
(Figure 1B). From this analysis it was determined that Bauer alkyl-
amide 11 (Figure 2A) was present at a concentration of 0.05 μM
and therewas no trace ofBauer ketone 23 (Figure 2A) in 1μg/mLof
fraction 3. Previously published studies conducted by our labora-
tory found that Bauer alkylamide 11 and Bauer ketone 23, at con-
centrations of 3.55 and 0.83 μM, respectively, contributed to the
inhibition of PGE2 production. Therefore, a 3.5 μM concentration
of chemically synthesized Bauer alkylamide 11 and a 0.83 μMcon-
centration of Bauer ketone 23 were added to 1 μg/mL of fraction 3
toproduce an enriched fraction 3.E. angustifolia fraction 3, enriched
fraction 3, and combinations of individual constituents and frac-
tion 3 were evaluated after an 8 h treatment with the RAW264.7
cells for PGE2 and NO production, showing significant PGE2
inhibitionwith all treatments and significantNO inhibitionwith the
combination of chemically synthesized Bauer alkylamide 11 and
Bauer ketone 23 and each constituent individually (Figure 2B). The
enriched fraction 3 was found to have significantly greater PGE2
inhibition capabilities than the fraction by itself. Cytotoxic effects
were not identified with any of the five E. angustifolia fractions or
with the enriched fraction or combinations of fraction and con-
stituents (data not shown).
Gene expressionwas analyzedwithGeneChipMouseGenome
430A 2.0 Arrays to identify target genes and determine pathways
Figure 2. (A) Structures and nomenclature for Bauer alkylamide 11 and Bauer ketone 23. (B) LPS-induced PGE2 and NO production in RAW264.7 cells
treated with E. angustifolia fraction, enhanced fraction, and chemically synthesized Bauer alkylamide 11 and Bauer ketone 23. The black bars represent PGE2
levels, and the white bars represent NO levels after induction with 1 μg/mL LPS and treatment (N = 3). All treatmentsþ LPS were compared to mediumþ
DMSOþ LPS control that was set at 100%PGE2 production (2.5 ng/mL) andNOproduction (18.8 ng/mL). The treatments without LPSwere compared to the
mediumþ DMSO control set at 100% PGE2 production (0.05 ng/mL) and NO production (∼0 ng/mL), identifying no significant differences with treatment for
either end point. Quercetin was used as a positive control for both studies and showed significant inhibition of PGE2 and NO production (p < 0.0001). / and //
are representative of p < 0.05 and p < 0.001, respectively. Each bar represents percent of control ( standard error. Parallel cytotoxicity screens were
conducted yielding no significant cytotoxicity with any of the treatments or combination of treatments (data not shown).
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leading to the inhibition of PGE2 production in the RAW264.7
mouse macrophage cells with selected treatments from Figure 2B
treated for 8 h. The medium þ DMSO control was compared to
themediumþDMSOþLPS control to establish that the expected
genes were differentially expressed. With a FDR of 0.001% 3354
differentially expressed (DE) genes were identified between the
controls, which corresponded with the DE genes identified by
Hammer et al. (21). Of these 3257 DE genes, 1253 had increased
expression levels (5.5% of total probe sets) and 2004 (8.9% of
total probe sets) had decreased expression levels, with 731 genes
decreased at least 50%below the expression level of themediumþ
DMSO control and 951 genes increased at least 50% above the
expression level of mediumþDMSO control after LPS treatment,
which represented 3.2 and 4.2% of the total probe sets, respec-
tively. Genes that were increased by the LPS treatment were
involved in the inflammatory response, cell cycle, cell signaling,
and cell proliferation, and those genes that were decreased were
involved in immune response, cell death, and cell motility.
In the search for DE genes between the medium þ DMSO þ
LPScontrol,E. angustifolia fraction 3þLPS, enriched fraction3þ
LPS, and the combination of Bauer alkylamide 11 þ Bauer
ketone 23þLPS, no genes were identified with a FDR below
50%. The eight DE genes that were identified between LPS-
treated samples with FDRs between 50 and 75% were analyzed
by MetaOmGraph (24) indicating that none were genuine DE
genes. Figure 3A provides a visual representation of the general
gene expression patternwith all five treatments through the use of
hierarchical clustering. Two clusters can be identified, one con-
taining the mediumþDMSO control and the other consisting of
all samples treatedwithLPS.Figure 3B represents changes in gene
expression level with the different treatment groups, consistent
with the analysis showing the LPS effect with the controls,
without any differences between each treatment þ LPS.
To obtain a more thorough understanding of the effect of
E. angustifolia fraction 3, enriched fraction 3, the combination of
Bauer alkylamide 11 and Bauer ketone 23, and these constituents
individually on gene expression, qRT-PCRwas used to produce a
time course for genes expected to be modulated by Echinacea.
Genes chosen for this analysis included COX-1, COX-2, TNF-R,
iNOS, and GADPH. These studies indicated that COX-2 gene
expression is not significantly different throughout the time
course from 0.5 to 24 h (Figure 4B). The only significant increase
in COX-2 gene expression was with the LPS-treated samples
compared to the mediumþDMSO control. TNF-R gene expres-
sion was significantly increased with treatment of the RAW264.7
cells with Bauer ketone 23 at the 0.5 h time point compared to the
medium þ DMSO þ LPS control (Figure 4C,E). At the 1 h time
point TNF-R gene expression was significantly decreased with
treatment of Bauer alkylamide 11 (Figure 4C,E). When gene
expression analysis for TNF-R was carried out to 24 h, a signifi-
cant decrease in gene expression was identified for E. angustifolia
fraction 3þ LPS, enriched fraction 3þ LPS, and combination of
Bauer alkylamide 11 and Bauer ketone 23 þ LPS as well as with
each individual constituent þ LPS compared to the medium þ
DMSO þ LPS control (Figure 4C,E). Treatments were also car-
ried out without LPS showing no significant difference in TNF-R
gene expression compared to themediumþDMSOcontrol (data
not shown). LPS-induced TNF-R protein production was also
analyzed, indicating that each treatment þ LPS, except for the
synthetic Bauer ketone 23, was capable of significant inhibition
(Figure 5). A significant difference in iNOS gene expression was
identified at the 24 h time point, indicating an increase in iNOS
mRNA with the enriched fraction 3 compared to the medium þ
DMSO þ LPS control (Figure 4D,F). The expected LPS induc-
tion of the RAW264.7 macrophage cells was identified with the
increase of COX-2, TNF-R, and iNOS genes after treatment with
themediumþDMSOþLPS control compared to themediumþ
DMSO control. GADPH was selected as the housekeeping gene
for the experiments, indicating no change in mRNA levels with
any of the treatments during the time course from0.5 to 24h (data
not shown). COX-1 mRNA was shown to increase at the 24 h
time point after treatment withE. angustifolia fraction 3, enriched
fraction 3, Bauer alkylamide 11, and Bauer ketone 23 compared
to the medium þ DMSO þ LPS control, although the combina-
tion of Bauer alkylamide 11 and Bauer ketone 23 did not signifi-
cantly change the mRNA levels.
Protein levels of COX-1, COX-2, and R-tubulin were assessed
after the treatment with the E. angustifolia fraction 3, enriched
fraction 3, and the combination of synthetic Bauer alkylamide 11
and Bauer ketone 23 (Figure 6), Bauer alkylamide 11 (Figure 7),
and Bauer ketone 23 (Figure 8). From these analyses it was shown
Figure 3. (A) Hierarchical cluster analysis of differentially expressed
genes in RAW264.7 mouse macrophages. A total of 3354 differentially
expressed probe sets were identified comparing the medium þ DMSO
control to the mediumþ DMSOþ LPS control with a FDR of 0.001%, with
no differentially expressed genes identified between treatments with LPS.
On the heatmap, the rows represent the genes and the columns represent
the treatments. The red color is indicative of low gene expression, and
green is indicative of high gene expression. Treatments are labeled as
follows: M0 = medium þ DMSO control, M1 = medium þ DMSO þ LPS
control, FR = E. angustifolia fraction 3, EN = E. angustifolia fraction 3
enriched with synthetic Bauer alkylamide 11 and Bauer ketone 23, and
AK = combination of synthetic Bauer alkylamide 11 and Bauer ketone 23.
(B) Standardized log signal for the two clusters identified in the analysis
represents changes in gene expression level with different treatment
groups. The number of probe sets is given in parentheses on the right
above the cluster graph.
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that there was a significant increase in COX-2 protein with
fraction 3 at 1 and 5 μg/mL, as well as with Bauer ketone 23 at
5 μM. Interestingly, there was a significant decrease in COX-1
protein with the treatment of fraction 3 at 5 μg/mL, yet R-tubulin
protein level remained unchanged. Protein levels of LPS-induced
iNOS were also assessed after treatment with enriched fraction 3,
the combination of Bauer alkylamide 11 and Bauer ketone 23,
and these constituents individually, showing no significant differ-
ences between treatments (ranging from 97.7 ( 23.5 to 101.1 (
21.7% of control) and medium þ DMSO þ LPS control after a
24 h treatment .
COX-2 activity (Figure 9) was analyzed after treatment of the
RAW264.7 macrophage cells for 8 h with E. angustifolia fraction
3 þ LPS, enriched fraction 3 þ LPS, the combination of Bauer
alkylamide 11 and Bauer ketone 23þ LPS, and the synthetic
constituents individually þ LPS.
To further examine the effect of the E. angustifolia fraction 3,
enriched fraction, the combination of Bauer alkylamide 11 and
Bauer ketone 23, and these compounds individually on the LPS-
induced inflammatory response in the RAW264.7 mouse macro-
phage cell line at the 24 h treatment time, cell culture supernatants
were analyzed on a multiplex assay system. Of the 32 cytokines/
chemokines, 15 (including the TNF-R protein data presented
above) showed significant treatment differences compared to
the medium þ DMSO þ LPS control (Table 2). All cytokines/
chemokines displayed inTable 2 exceptMIP-1b showeddecreases
in protein concentration with treatments including the synthetic
Bauer constituents either alone or in combination þ LPS com-
pared to the medium þ DMSO þ LPS control. The enriched
fraction þ LPS significantly decreased IL-1b, IL-4, IL-12(p40),
KC, LIF, LIX, and MIG protein levels compared to control
(Table 2). E. angustifolia fraction 3 þ LPS showed significant
inhibition of LIF protein levels compared to control (Table 2).
Many cytokines/chemokines showed a trend (0.05< p<0.10)
toward significant decreases including the enriched fraction þ
LPS impact on Eotaxin, IL-7 MIP-1b, and RANTES.
DISCUSSION
Amajor finding in this study is thatby enriching anE. angustifolia
fraction (1 μg/mL) with Bauer alkylamide 11 (3.5 μM) and Bauer
Figure 4. (A) Legend for qRT-PCR treatments. (B) Analysis of qRT-PCR time course for COX-2 gene expression.N = 3 for each treatment. Standard errors
ranged from 0.02 to 0.16 TNF-R transcript log starting quantity for all treatments and time points. (C) Analysis of qRT-PCR time course for TNF-R gene
expression. N = 3 for each treatment. Standard errors ranged from 0.03 to 0.16 TNF-R transcript log starting quantity for all treatments and time points. / and
// are representative of p < 0.05 and p < 0.01, respectively. (D) Analysis of qRT-PCR time course for iNOS gene expression. N = 3 for each treatment.
Standard errors ranged from 0.03 to 0.24 for all treatments and time points. / and // are representative of p < 0.05 and p < 0.01, respectively. (E) qRT-PCR
analysis at time points with significant treatment effects for TNF-R gene when compared to the mediumþ DMSOþ LPS control. / and // are representative
of p < 0.05 and p < 0.01, respectively. Bars represent the mean( standard error. (F) qRT-PCR analysis at time point with significant treatment effect for iNOS
gene when compared to the mediumþ DMSOþ LPS control. / and // are representative of p < 0.05 and p < 0.01, respectively. Bars represent the mean(
standard error.
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ketone 23 (0.83 μM) amore potent inhibition of the LPS-induced
inflammatorymediator, PGE2,was identified compared to that seen
with the fraction alone after an 8 h treatment on the RAW264.7
macrophage cells. From these results, it appears that Bauer alkyl-
amide 11 andBauer ketone 23 accounted for amajority of the PGE2
inhibitory capabilities of the fraction, but they did not show evi-
dence of additivity. This finding indicates that it is possible to mani-
pulate an Echinacea product to target a specific bioactivity after the
discovery of constituents of importance as well as concentrations
required to elicit the desired effect. Having the ability to target
Figure 6. (A) Analysis of LPS-induced COX-1, COX-2, and R-tubulin protein levels in RAW264.7 cells with representative Western blots for E. angustifolia
fraction 3, enriched fraction 3, and the combination of Bauer alkylamide 11 and Bauer ketone 23.N = 3 for each blot. (B) Semiquantitative representation of the
blots from A. Bars represent mean percent of mediumþ DMSOþ LPS control( standard error. LPS-induced COX-2 protein from 24.3( 8.2% average for
themediumþDMSO control to 100( 20.6% average for the mediumþDMSOþ LPS control. There was no significant LPS effect for the mediumþDMSO
control with COX-1 (96.9( 1.8% of control average) or R-tubulin (104.4( 3.4% of control average) on protein level compared to the mediumþ DMSOþ
LPS control. Quercetin was used as a positive control at 100 μM for the reduction of LPS induced COX-2 protein 41.3( 16.9% of control. Quercetin did not
significantly affect LPS-induced COX-1 (85.3( 3.2% of control average) or R-tubulin (109.6( 16.7% of control average). / and // are representative of
p < 0.05 and p < 0.01, respectively, when compared to medium þ DMSO þ LPS control.
Figure 5. LPS-induced TNF-R production in RAW264.7 cells treated with E. angustifolia fraction, enhanced fraction, and chemically synthesized Bauer
alkylamide 11 and Bauer ketone 23. The light gray bars represent TNF-R levels after treatment with Echinacea fraction, enriched fraction or compounds. The
dark gray bars represent TNF-R levels after induction with 1 μg/mL LPS and treatment (N = 3). All treatmentsþ LPS were compared to mediumþ DMSOþ
LPS control. The treatments without LPS were compared to the mediumþ DMSO control. (p < 0.0001). / and // are representative of p < 0.05 and p < 0.01,
respectively. Each bar represents mean( standard error.
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specific bioactivities with Echinacea products would be very im-
portant in the development of botanical products that are used for
specific medicinal purposes. Major studies of the clinical efficacy of
Echinacea to treat symptoms of the common cold or other upper
respiratory infections have been ambiguous due to several con-
founding factors, including the use of different or undefined
preparations of this botanical (25, 26). To characterize which
constituents are necessary for particular medicinal outcomes and
at what concentrations, studies are needed to provide concrete
evidence of in vivo effectiveness in both animals and humans, as
well as bioavailability of these constituents both individually and as
a complex mixture.
Our studies set out to understand the mechanism of action
leading to the inhibition of PGE2 production in the RAW264.7
cells by Echinacea after an 8 h treatment period (12, 13). Using
microarray analysis and qRT-PCR, it became apparent that our
Echinacea treatments were not acting on the gene expression level
for COX-2 or other potentially immune-related transcripts.
However, Western blot analysis led to the intriguing finding that
E. angustifolia fraction 3 and Bauer ketone 23 could increase
COX-2 protein levels after an 8 h treatment, yet also have the
ability to inhibit PGE2 production at that same time point. These
studies directed the way to another key observation, which is
supported by previous literature (17), that the identified inhibi-
tion of LPS-induced PGE2 production with E. angustifolia frac-
tion 3, enriched fraction 3, the combination ofBauer alkylamide 11
and Bauer ketone 23, and these constituents individually on the
RAW264.7 cells occurs in part through the inhibition of COX-2
activity. The discovery of COX-2-specific inhibitors has been the
objective in the development of several drugs for relief of inflam-
matory symptoms. Aspirin was one of the first COX inhibitors
shown to act through acetylation of an active-site serine residue (27).
OtherCOXinhibitors callednonsteroidal anti-inflammatorydrugs
(NSAIDS) act as competitive inhibitors of COX by reversibly
engaging the binding site for arachidonic acid. Understanding the
kinetics behind the inhibition of COX-2 activity with these
Echinacea treatments is critical to understanding the plant’s
possible usefulness as an anti-inflammatory agent. The results
obtained herein allow us to hypothesize a mechanism for the
inhibition of PGE2productionbased on increasedCOX-2 protein
levels and decreased COX-2 activity. One model that could
explain these observations would be that these Echinacea pro-
ducts are directly inhibiting COX-2 activity by competing with
arachidonic acid for the active site of this enzymewhile at the same
time blocking ubiquitination that would normally target the
enzyme for degradation. Thismodel is consistentwith the observed
decrease in COX-2 activity, decrease in PGE2 production, and
increase in COX-2 protein, with no change in gene expression.
TNF-R is a cytokine regulated through the cannabinoid recep-
tors and, therefore, modulated through the binding of Echinacea
alkylamides to the CB2 receptor. Gertsch et al. performed a
RT-PCR time course experiment to understand how Echinaforce
modulatedTNF-Rgene expression inmonocytes/macrophages (4).
The results from this study showed that LPS-induced TNF-R
mRNA decreased around 10 h after treatment of the alkylamide-
rich preparation, with a steady decline until approximately 25 h.
Other findings from this study indicated that it was the alkylamide
constituents that acted on theCB2 receptors tomodulate theTNF-
R gene expression at a concentrationas lowas 0.5μM(4).Recently,
Chicca et al. provided further evidence that N-alkylamides were
major contributors to the synergistic inhibitory effect on TNF-R
identified upon combination of radix andherba tinctures acting via
Figure 7. (A) Analysis of LPS-induced COX-1, COX-2, andR-tubulin protein levels in RAW264.7 cells with representativeWestern blots for Bauer alkylamide
11.N = 3 for each blot. (B) Semiquantitative representation of the blots from A. Bars represent mean percent of mediumþ DMSOþ LPS control( standard
error. LPS-induced COX-2 protein from 19.1( 6.2% average for the mediumþ DMSO control to 100( 10.9% average for the mediumþ DMSOþ LPS
control. Therewas no significant LPS effect for themediumþDMSOcontrol with COX-1 (83.4( 3.0%of control average) orR-tubulin (94.7( 2.1%of control
average) on protein level compared to the mediumþ DMSOþ LPS control. Quercetin was used as a positive control at 100 μM for the reduction of LPS-
induced COX-2 protein to 71.4( 3.1% of control. Quercetin did not significantly affect LPS-induced COX-1 (96.1( 6.5% of control average) or R-tubulin
(98.0( 4.3 of control average). / and // are representative of p < 0.05 and p < 0.01, respectively, when compared to medium þ DMSOþ LPS control.
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CB2 receptors (28). Our qRT-PCR time course was carried out
to 24h, showing a significant decrease inLPS-inducedTNF-R gene
expression with the alkylamide-rich E. angustifolia fraction 3,
enriched fraction 3, combination of alkylamide and ketone, and
Figure 8. (A) Analysis of LPS-induced COX-1, COX-2, andR-tubulin protein levels in RAW264.7 cells with representativeWestern blots for Bauer ketone 23
individually and in combination withE. angustifolia fraction 3.N = 3 for each blot. (B) Semiquantitative representation of the blots fromA. Bars represent mean
percent ofmediumþDMSOþ LPScontrol( standard error. LPS inducedCOX-2 protein from4.8( 2.8%average for themediumþDMSOcontrol to 100(
12.0% average for the mediumþ DMSOþ LPS control. There was no significant LPS effect for the mediumþ DMSO control with COX-1 (95.4( 3.3% of
control average) orR-tubulin (103.9( 7.3% of control average) on protein level compared to the mediumþ DMSOþ LPS control. Quercetin was used as a
positive control at 100μM for the reduction of LPS-inducedCOX-2 protein to 53.0( 15.7% of control. Quercetin did not significantly affect LPS-inducedCOX-1
(95.5 ( 2.2% of control average) or R-tubulin (91.8 ( 9.7 of control average). / and // are representative of p < 0.05 and p < 0.01, respectively, when
compared to medium þ DMSO þ LPS control.
Figure 9. LPS-induced COX-2 activity in RAW264.7 cells treated with E. angustifolia fraction, enhanced fraction, and chemically synthesized Bauer
alkylamide 11 and Bauer ketone 23. The black bars represent COX-2 activity levels after induction of cells with 1 μg/mL LPS and treatment (N = 3). All
treatments with added LPS were compared to a mediumþ DMSOþ LPS control that was set at 100% COX-2 activity (5.8 nmol/min/mL). The treatments
without LPS were compared to the mediumþ DMSO control set at 100% COX-2 activity (2.4 nmol/min/mL), identifying no significant differences. Quercetin
was used as a positive control for both studies and showed significant inhibition of COX-2 activity (p < 0.0001). / and // are representative of p < 0.05 and
p < 0.01, respectively. Each bar represents percent of control( standard error.
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the individual constituents, corresponding with these earlier find-
ings (4 , 28), although the concentration of alkylamide in our
studies was slightly higher at 3.55 μM than that reported the study
by Gertsch et al. (4). Our studies indicate that these treatments,
excluding Bauer ketone 23, also significantly inhibited TNF-R
protein production. Due to the similarity in our results it could
be hypothesized that our Echinacea treatments are also acting
through binding the cannabinoid receptors, with the exception of
synthetic Bauer ketone 23 (0.83 μM), which also showed a signifi-
cant decrease in TNF-R gene expression at the 24 h time point.
An interesting finding from our studies is that Bauer ketone 23
(0.83 μM) alone did not significantly modulate TNF-R protein
levels. Egger et al. determined that ketones, analyzed at 3% (v/v) in
DMSO,donot appear tomediate their immunomodulatory effects
through the cannabinoid receptors (3), and therefore it is likely that
Bauer ketone 23 acts through a different mechanism to inhibit the
noted TNF-R gene expression identified in our qRT-PCR studies
after a 24 h treatment, although these findings do not rule out
the possibility that Bauer ketone 23 may interfere indirectly with
the endocannabinoid system in a manner that could lead to the
inhibition of TNF-R expression.
The results obtained from the multiplex assay would indicate
that treatments including the enriched fraction, the combination
ofBauer alkylamide 11 andBauer ketone 23, or these constituents
individually act in an immunosuppressive manner, with the abi-
lity to inhibit the accumulation of several cytokines/chemokines.
The inhibitionof chemokinesmay limit the recruitment of specific
cell populations. For example, reduction of KCmay reduce neutro-
phil migration, whereas a decrease in LIX,MCP-1, MIP-1R, and
MIP1-β may limit recruitment of inflammatory monocytes/
Table 2. Milliplex Data Examining Accumulation of 15 Cytokines/Chemokines in RAW264.7 Cellsa
protein concentrations after 24 h treatment to RAW264.7 cells
cytokine/chemokine
medium þ
DMSO þ LPS
E. angustifolia
fraction 3 þ LPS
enriched
fraction 3 þ LPS
Bauer alkylamide 11 and
Bauer ketone 23 þ LPS
Bauer alkylamide
11 þ LPS
Bauer ketone
23 þ LPS
Eotaxin (pg/mL) 56.6 ( 4.5 48.3 ( 0.9 43.8 ( 5.0 45.8 ( 2.2 42.0 ( 4.8 39.0 ( 3.4
0.209 0.067 0.113 0.041 0.018
IL-1b (pg/mL) 220.1 ( 46.4 142.6 ( 5.8 120.2 ( 13.9 152.0 ( 5.2 114.6 ( 20.1 81.0 ( 12.7
0.052 0.017 0.081 0.013 0.003
IL-4 (pg/mL) 7.0 ( 0.6 6.0 ( 0.2 4.8 ( 0.4 5.8 ( 0.4 5.0 ( 0.6 4.5 ( 0.3
0.225 0.017 0.1614 0.024 0.008
IL-6 (ng/mL) 24.6 ( 0.2 24.2 ( 0.2 23.8 ( 0.2 24.4 ( 0.1 23.3 ( 0.6 19.8 ( 2.1
0.821 0.621 0.886 0.467 0.017
IL-7 (pg/mL) 8.7 ( 0.6 7.1 ( 0.6 6.1 ( 0.5 6.4 ( 0.8 5.3 ( 1.6 4.1 ( 0.1
0.270 0.088 0.127 0.032 0.007
IL-12 (p40) (pg/mL) 22.8 ( 5.0 7.7 ( 5.0 7.4 ( 1.4 7.5 ( 3.2 22.0 ( 0.1 2.7 ( 0.6
0.051 0.050 0.048 0.764 0.016
IL-15 (pg/mL) 86.6 ( 14.6 58.7 ( 2.4 57.6 ( 6.7 63.0 ( 5.5 48.2 ( 15.1 43.5 ( 5.7
0.119 0.107 0.180 0.041 0.025
KC (pg/mL) 352.6 ( 28.1 269.7 ( 7.8 216.2 ( 24.4 283.2 ( 38.7 245.3 ( 27.3 228.8 ( 34.2
0.110 0.016 0.173 0.047 0.026
LIF (ng/mL) 1.9 ( 0.3 1.2 ( 0.1 0.9 ( 0.2 1.2 ( 0.1 0.8 ( 0.2 0.6 ( 0.2
0.019 0.005 0.021 0.002 0.001
LIX (ng/mL) 5.2 ( 0.6 4.5 ( 0.3 3.6 ( 0.4 4.3 ( 0.4 3.3 ( 0.7 3.9 ( 0.5
0.356 0.038 0.194 0.018 0.0897
MCP-1 (ng/mL) 14.1 ( 0.3 12.8 ( 363.9 12.9 ( 0.7 1.3 ( 628.4 9.9 ( 1.6 13.2 ( 0.8
0.391 0.422 0.659 0.015 0.558
MIG (pg/mL) 26.0 ( 5.3 17.8 ( 1.5 15.0 ( 1.2 21.3 ( 1.0 13.0 ( 3.7 15.4 ( 3.1
0.114 0.044 0.347 0.021 0.050
MIP-1a (ng/mL) 10.5 ( 0.4 7.5 ( 1.2 9.5 ( 0.6 7.7 ( 2.0 6.8 ( 1.8 10.2 ( 0.03
0.144 0.279 0.5871 0.021 0.558
MIP-1b (ng/mL) 38.9 ( 11.1 17.8 ( 4.0 11.7 ( 0.9 45.1 ( 20.0 30.6 ( 20.3 26.0 ( 5.9
0.129 0.075 0.938 0.1051 0.2614
RANTES (ng/mL) 3.2 ( 0.6 2.0 ( 0.5 1.7 ( 0.3 1.9 ( 0.3 0.9 ( 0.1 1.7 ( 0.1
0.112 0.053 0.095 0.006 0.046
aMilliplex analysis examined 32 cytokines/chemokines. Only cytokines/chemokines that are known to be strongly relevant to the macrophage response to inflammation are
included in the table. Each treatment was compared to the mediumþ DMSOþ LPS control. Only LPS-treated samples are displayed. Top numbers in table represent mean of
three replicates( standard error and bottom numbers indicate p values compared to the value for the mediumþ DMSOþ LPS control. Boldface p values represent statistical
significance (p < 0.05).
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macrophages. In general, a decrease in cytokines may decrease
cellular activation. A decline in IL-4 may inhibit T-helper cell
type 2 response, whereas a decline in IL-12 and MIG may limit
T-helper cell type 1/IFNγ-induced cell-mediated immune res-
ponses. Taken together, the reduction in thesemultiple chemokines/
cytokines may have beneficial effects in vivo at a resolution phase
of infection when the inflammatory immune response should
decline.
LPS-induced NO production was significantly inhibited by
treatments of synthetic Bauer alkylamide 11 andBauer ketone 23,
Bauer alkylamide 11 individually, and Bauer ketone 23 indivi-
dually after a 24 h incubation on the RAW264.7 mouse macro-
phage cells. From the gene expression data it was determined that
the enriched fraction 3 showed a significant increase in iNOS
mRNA compared to the medium þDMSO þ LPS control,
although NO production was not increased. Enriched fraction 3,
Bauer alkylamide 11, andBauer ketone 23were shown to have no
effect onLPS-induced iNOSprotein levels after a 24h incubation.
Previous studies on Echinacea extract treated RAW264.7 cells
incubated for 23 h determined that the extracts were capable of
NO inhibition, not through direct scavenging of the free radical
but through the inhibition of iNOS (15). Chen et al. also demon-
strated that alkylamides were capable of inhibiting LPS-induced
NO production after a 24 h incubation in the RAW264.7 cell
line, including isolated Bauer alkylamide 11, with an ID50 of
23.9 μM (14). Our prior studies had also indicated that Bauer
ketones could significantly inhibit NO production at concentra-
tions as low as 1 μM (12). The findings from the present study
indicate that compounds from Echinacea target NO production,
and future studies will concentrate on the mechanism leading to
the identified inhibition.
Although immunostimulatory effects have been identified in
other studies using water extracts ofEchinacea (2), it is important
to point out that the results acquired from this study provide
evidence that through the enrichment of anEchinacea fractionwith
the addition of key anti-inflammatory constituents, it is possible to
enhance the anti-inflammatory potential of this botanical. It is also
of interest to note that no additive or synergistic effects were
identified with treatments that combined synthetic Bauer alkyl-
amide 11 and Bauer ketone 23 in the PGE2 screening, although
the addition of these compounds to the E. angustifolia fraction
proved to increase anti-inflammatory potential. This research also
has led to a proposedmechanism in whichEchinacea fractions and
pure constituents may inhibit PGE2 and increase COX-2 protein
expression by competitively binding the COX-2 enzyme while
blocking ubiquitination and, therefore, degradation of the protein.
The model described was established on the basis of the results
obtained from our COX-2 protein and activity studies indicating
that enriched fraction and synthetic Bauer ketone 23 increased
COX-2 protein level and the E. angustifolia fraction, enriched
fraction, combination of constituents, and individual constituents
were all capable of a significant inhibition of COX-2 enzyme
activity, therefore accounting for the identified inhibition of PGE2
production.
ABBREVIATIONS USED
PI, plant introduction; DMSO, dimethyl sulfoxide; PGE2,
prostaglandinE2;NO, nitric oxide; LPS, lipopolysaccharide;GC-
MS, gas chromatography-mass spectrometry; HPLC, high-
performance liquid chromatography.
SAFETY
LPS compounds are pyrogenic and should not be inhaled or
allowed to enter the bloodstream.
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